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What is HAN?
The South Carolina Department of
Health and Environmental Control (SC
DHEC) and the Division of Emergency
Management have partnered to
provide a robust, interactive, web-
based tool that provides alerting and
notification capability.  This tool is
known as REACH SC and is used
jointly as a notification system for
urgent public health threats and
events that require a statewide
emergency response.
The Health Alert Network (HAN) is a
component of REACH SC that SC
DHEC uses for emergency
communication with key public health
response personnel and medical
professionals throughout the state.
REACH SC provides 24 hour access
and is used by SC DHEC to provide
three levels of notification capabilities:
health alerts, health advisories, and
health updates.  These notifications
can be sent to public health and
medical professionals by fax, phone,
and email.  This new form of
redundant communication allows for
rapid notification and response in the event of a
potential or actual public health emergency.
Rotavirus is the most common cause of severe
gastroenteritis in infants and young children worldwide.
While rotavirus gastroenteritis results in relatively few
childhood deaths in the United States, nearly every child in
the United States is infected with rotavirus by age 5 years.
Severe dehydrating gastroenteritis occurs primarily among
children aged 3-35 months.  The Advisory Committee on
Immunization Practices (ACIP) published Prevention of
Rotavirus Gastroenteritis Among Infants and Children in
the Morbidity and Mortality Weekly Report (MMWR) on
August 11, 2006.  The document can be found on the CDC
Web site at:
h t t p : / / w w w. c d c . g o v / m m w r / p r e v i e w / m m w r h t m l /
rr5512a1.htm.
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Why is it important?
In times of an emerging public health threat, having the
latest information in the hands of our front-line clinicians
regarding clinical presentation, case definition, activities
required and impact to South Carolina are critical to a timely
response.  The HAN is an important notification tool to
ensure information-sharing among public health
departments, healthcare organizations, and other first
responder communities.
What does it provide?
Since it’s inception in 2003, the South Carolina Health
Alert Network has sent out over 114 public health
notifications via Health Alerts, Advisories, and Updates.
Examples of content from previous notifications include:
• Enhanced surveillance and the clinical indicators
of possible E. coli O157:H7 infection
• Medical management of chlorine exposure
• Interim guidance for businesses with employees
returning to the United States from areas with
SARS
• Multi-state investigation of potential rabies
exposure at a summer camp
The SC HAN provides not only information about activities
going on across the country, but also important information
for clinicians in South Carolina to use in response to both
local and state-level events of public health significance.
How can you sign up?
All health alerts, advisories, and updates that originate
from the CDC or SC DHEC are sent via the Health Alert
Network.  It is important that public health and medical
professionals are notified in the event of a public health
emergency and REACH SC provides the rapid means of
communicating with these professionals.  Once an alert
notification is received, health professionals will be able
to quickly respond in a timely manner.  Without registering
for REACH SC, however, health care professionals may
miss out on receiving critical information.  Registering for
ReachSC is simple and there is no cost involved.  To
register for REACH SC, please contact Shana LeGrand
Dorsey by call ing 803-898-0431 or by email at
legransd@dhec.sc.gov.
South Carolina Immunization Registry
Rodney Saylor, Database Administrator
Immunization Division
Elona Rhame, Nurse Consultant
Immunization Division
Immunization registries are confidential, computerized
information systems that collect vaccination data within a
geographic area. By consolidating vaccination records from
multiple health-care providers, generating reminder and
recall notifications, and assessing vaccination coverage,
registries serve as key tools to increase and sustain high
vaccination coverage. One of the national health objectives
for 2010 is to increase to 95 percent the proportion of
children 6 years old or younger who participate (i.e., have
two or more vaccinations recorded) in fully operational,
population-based immunization registries.
The new South Carolina immunization registry is part of
the DHEC ‘Client Automated and Reporting System
(CARES).  This Web-accessible registry will be available
to both DHEC and private immunization providers.  The
new registry has recently been implemented in eight
counties.  All previous DHEC immunization data for the
eight counties have been added to the CARES
Immunization Registry.   The registry will be operational
statewide by May 2007.
Currently, the registry meets ten of the twelve Minimum
Functional Standards for Immunization Registries defined
In February 2006 the Food and Drug Administration (FDA)
licensed a new rotavirus vaccine (RotaTeq®, produced by
Merck and Company, Whitehouse Station, New Jersey) for
use among U.S. infants.  RotaTeq® is a live, oral vaccine
that contains five reassortant rotaviruses developed from
human and bovine parent rotavirus strains.  This
pentavalent rotavirus vaccine (PRV) contains no
preservatives or thimerosal.
The ACIP recommends routine vaccination of U.S. infants
with three doses of PRV administered orally at ages 2, 4,
and 6 months. The first dose should be administered
between ages 6 and 12 weeks.  Subsequent doses should
be administered at four to ten-week intervals, and all three
doses of vaccine should be administered by age 32
weeks. Vaccination should not be initiated for infants aged
>12 weeks because of insufficient data on safety of the
first dose of rotavirus vaccine in older infants. Vaccine
should not be administered after age 32 weeks because
of insufficient data on the safety and efficacy of rotavirus
vaccine in infants after this age.
Rotavirus vaccine may be administered along with other
routinely administered childhood vaccines.  Precautions
to vaccination include acute gastroenteritis, moderate-to-
severe illness, preexisting chronic gastrointestinal
disease, history of intussusception, and altered
immunocompetence.
Enrolled VAFAC (Vaccine Assurance For All Children)
providers may order rotavirus vaccine for VAFAC eligible
infants through the DHEC Immunization Division.  For
VAFAC enrollment information or for more information
regarding rotavirus vaccination, contact the DHEC
Immunization Division at 1-800-277-4687.
(HEALTH ALERT NETWORK cont'd from Page 1)
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by the CDC.  These Standards have been met by the new
registry:
• It electronically stores data on all NVAC-
approved core data elements
• It enables access to and retrieval of
immunization information at the time of
encounter
• It protects confidentiality of health information
• It ensures security of health information
• It automatically determines the routine
childhood immunizations needed
• It automatically identifies individuals due/late
for immunizations to enable the production
of reminder/recall notifications
• It automatically produces immunization
coverage reports by providers, age groups,
and geographic areas
• It produces official immunization records (Day
Care and School Certificates)
• It promotes accuracy and completeness of
registry data
The Minimal Functional Standards for Immunization
Registries can be found at http://www.cdc.gov/nip/registry/
st_terr/tech/stds/min-funct-stds2001.htm.   Standard #2,
populating from the vital records system, and Standard
#7, exchanging immunization records using HL7
standards, are in development.
Once a county public health department implements the
CARES Immunization Registry, private providers in that
county are encouraged to request access.  A Memorandum
of Agreement (between DHEC and the practice) initiates
the process.  Individual users within the practice must
sign a User Agreement.  DHEC will provide training and
support.  System access is via the Internet.
The first private pilot project with a Sumter County provider
will begin in October 2006.  Other counties where the
registry is operational include:  Kershaw, Lee, Union,
Clarendon, Cherokee, Anderson, and Greenwood.
For more information regarding the South Carolina
immunization registry, contact the DHEC Immunization
Division at 1-800-277-4687.
Cryptosporidiosis: Is A Change In Test
Methodology Identifying More Cases?
Dan Drociuk
Director, Epi Response/Enhanced Surveillance
Division of Acute Disease Epidemiology
Robert T. Ball, Jr, MD, MPH
Infectious Disease Consultant and Epidemiologist
DHEC Public Health Regions 6  and 7
In recent months the South Carolina Department of Health
and Environmental Control (SC DHEC) has received an
increased number of reports of cases of laboratory-
confirmed cryptosporidiosis among children and adults
as compared to recent years.  Cases associated in time
and geographic location (Charleston, Berkeley, and
Dorchester counties) have led to further investigations to
determine causal associations. Many of these cases
appear to be related to recreational water exposure, which
is the primary method of spread of this illness in South
Carolina, especially during the summer months; however,
no single point-source exposure was identified.
A survey of laboratorians and physician practices within
the region indicate that the increase in reports of crypto
may be due in part to increased testing for crypto by rapid
EIA methods on stool samples. This differs from historical
methods for the detection of oocyts via microscopic
examination of stool specimens.  It is unclear whether
this investigation is documenting the natural background
prevalence of cryptosporidium, identifying a true recent
increased incidence, or both.
Clinical Information
Cryptosporidiosis is a diarrheal disease caused by
microscopic parasites of the genus Cryptosporidium. Both
the disease and the parasite are commonly known as
“crypto.” Once an animal or person is infected, the parasite
lives in the intestine and passes in the stool. The spore
phase of the parasite’s life cycle, or “oocyst”, allows it to
survive outside the body for long periods of time and makes
it very resistant to chlorine- based disinfectants. Crypto
may survive up to a week in swimming pools under
standard chlorination procedures.
The median incubation time for cryptosporidiosis is 7 days.
The most common symptom of Cryptosporidiosis is watery
diarrhea. Other symptoms may include dehydration,
weight loss, stomach cramps or pain, fever, nausea, and
vomiting. Some people with crypto will have no symptoms
at all. In immunocompetent people, the diarrheal disease
is self-limited, usually lasting 1-20 days. While the small
intestine is the site most commonly affected,
Cryptosporidium infections could possibly affect other
areas of the digestive or the respiratory tract. Shedding of
oocysts in stool may continue for up to two weeks after
symptom resolution.
Risk Factors for Cryptosporidium
People who are most likely to become infected with
Cryptosporidium include:
        • Swimmers who swallow water while swimming
in recreational swimming waters, lakes, rivers,
ponds, and streams
• Children who attend day care centers, including
diapered children
• Child care workers
• Parents of infected children
• Persons in contact with infected farm livestock,
petting zoo animals, or pets.
• International travelers
• Backpackers, hikers, and campers who drink
unfiltered, untreated water
(CRYPTOSPORIDIOSIS cont'd from Page 3)
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• Persons who drink from shallow, unprotected
wells
• Persons who swallow water from contaminated
sources
Diagnostic Tests and Laboratory Confirmation
• The detection of oocyts on microscopic
examination of stool specimens is diagnostic.
Unfortunately, routine laboratory examination of
stool for ova and parasites will not detect
Cryptosporidium species.
• The sucrose flotation method or formalin ethyl
acetate method is used to concentrate oocysts in
stool before staining with a modified Kinyoun acid-
fast stain.
• Monoclonal antibody-based fluorescein-
conjugated stain for oocysts in stool and an
enzyme immunoassay (EIA) for detecting antigen
in stool are available commercially.
• Because shedding can be intermittent, at least 3
stool specimens collected on separate days
should be examined before considering test
results negative. Oocysts are small (4-6 UM in
diameter) and can be missed in a rapid scan of a
slide.
Sources for Additional Information
Additional information regarding Cryptosporidiosis and
disease transmission in recreational water can be found
at:
• www.cdc.gov/healthyswimming/index.htm
• w w w. c d c . g o v / n c i d o d / d p d / p a r a s i t e s /
cryptosporidiosis
• American Academy of Pediatrics. Red Book: 2006
Report of the Committee on Infectious Diseases.
27th ed.
CHESS Hospital Deployment
Claire Youngblood, MA
Data Manager/ Program Coordinator
Division of Acute Disease Epidemiology
Carolina’s Health Electronic Surveillance System (CHESS)
has been used by DHEC’s regional public health
departments for more than two years.  CHESS allows
health care providers to submit disease reports through a
secure Web-based interface.  This replaces disease report
cards for many conditions.  The CHESS report is received
by the local public health department, investigated, and
then electronically forwarded to the DHEC Central Office
in Columbia.  A Central Office consultant reviews the
investigation and makes sure the reported disease meets
the case definition.  The consultant then electronically
submits the report to the Centers for Disease Control
(CDC).
CHESS is now available for external users, such as
hospitals and laboratories.  Winthrop University and Aiken
Regional Medical Center have already activated the system
and a number of other organizations will be connected to
CHESS within the next few weeks.  Participating
organizations will receive quick feedback on disease
reports and know that they are reporting disease in the
fastest way possible.  The ultimate goal of the new system
is to increase the speed and accuracy of disease reporting
while reducing paperwork.
Hospitals and other reporting health care providers who
are interested in using CHESS to submit reportable
conditions are urged to participate.  For more information,
please call the CHESS Help Desk at (800) 917-2093 or e-
mail Claire Youngblood at youngbhc@dhec.sc.gov.
On-line Viral Hepatitis Serology Course
Libby Greene, MSN, APRN, BC
Director, Surveillance Section/Hepatitis Coordinator
Division of Acute Disease Epidemiology
The Division of Viral Hepatitis at the Centers for Disease
Control and Prevention (CDC) now has an on-line hepatitis
serology course for physicians, nurses, and other health
care providers.  This course includes training on serologic
interpretation for hepatitis A, B, C, D, and E.  It takes
approximately 30-45 minutes to go through each section
of the course, take the tests, and complete the evaluation.
Continuing education credits for physicians (1.3 category
1 credits) and nurses (1.6 contact hours through the
American Nurses Credentialing Center’s Commission on
Accreditations) are available.
The course is on the CDC website at:
http://www.cdc.gov/ncidod/diseases/hepatitis/serology/
index.htm.
Rabies Update
Mary Helen Niemeyer, MD
DHEC Region 5 Medical Director
Rabies is an almost universally fatal viral infection
transmitted from the saliva and neural tissue of infected
mammals.  In the United States the incidence of dog rabies
and associated human infection has decreased during
the past 20 years, while the incidence of rabies in wildlife
(especially raccoons, skunks, and bats) has increased.
Bat strains of rabies virus account for over 50 percent of
the human cases of rabies diagnosed annually in the
United States.  Extensive field experience from the United
States and abroad has demonstrated that Post-Exposure
Prophylaxis (PEP) combining wound treatment, passive
immunization, and vaccination is uniformly effective in
   (Continued on Page 5)
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preventing human rabies when appropriately
implemented.
In South Carolina, mammal bites/scratches to humans
are required by state law (Rabies Control Act) to be
immediately reported to DHEC.  DHEC staff investigated
11,544 animal exposures in 2005 and 452 victims received
PEP through primary care/ER physicians.  Of the 2,741
animal heads that were submitted to the State Bureau of
Laboratories in 2005, 220 tested positive for rabies; the
vast majority were from raccoons (129) followed by 31
foxes, 21 skunks, 21 bats, 8 cats, 7 dogs, and 3 bobcats.
DHEC has a long history of partnering with physicians in
the management of animal bites/scratches. DHEC
provides rabies vaccine and Human Rabies Immune
Globulin (HRIG) and also consultation in the management
of animal exposures.  Responsibil ity for medical
management of rabies PEP administration, including
compliance with the recommended vaccination schedule,
resides with the treating private physician.  A new DHEC
policy directs several changes that are expected to improve
the interaction of consulting medical staff, improve
accountability for the costly PEP products, improve
documentation of activities associated with evaluation of
the circumstances of potential rabies exposures, assist
in educating private practitioners, and promote better
adherence to the recommended course of PEP.
When a DHEC staff member delivers PEP to a treating
physician’s office, it will be accompanied by the new DHEC
Rabies PEP Information Packet.  This includes:
1. DHEC Rabies form 3548 “Receipt for Delivery
of Rabies PEP Products”:  DHEC provides PEP
and requests completion of receipt of this
transaction by signatures of both the consulting
DHEC nurse/physician and the treating private
physician or other authorized person from the
practice.
2. DHEC Rabies form 1767 “PEP Schedule, Follow-
up, and Guidelines”:  This simplif ied
documentation of the recommended rabies PEP
schedule for the individual patient will have the
anticipated vaccination dates filled in. After
completion of the series, it is to be returned to the
local health department by the treating physician.
3. Rabies Vaccine Information Statement (VIS):  To
be given to the patient receiving the PEP
4. RIG/vaccine package insert
5. Name(s) and 24-hour contact number(s) of DHEC
consultants who can answer questions
regarding missed or delayed doses of rabies
vaccine, possible adverse vaccine reactions, or
other clinical management issues.
DHEC looks forward to continuing and improved
collaboration with our valuable physician partners in
achieving best practices for animal bite management in
South Carolina.  For questions or further information, call
the local health department or the DHEC Division of Acute
Disease Epidemiology at (803) 898-0861.
Mumps
Shirley Jankelevich, MD, MPH
Medical Epidemiologist
Division of Acute Disease Epidemiology
Definition:  A common childhood inflammatory disease
of the salivary glands with occasional serious
complications.
Etiology:  Mumps virus (paramyxovirus; RNA virus).  Also
called benign viral parotitis.
Epidemiology:  Worldwide distribution with man as the
only known reservoir.  Prior to the vaccine, about 50% of
children contracted mumps.
Transmission: Viral transmission occurs through
inhalation of respiratory droplets or by direct person-to-
person contact.
Infective Period: 2-3 days before symptoms until 9 days
after symptoms disappear. One third of cases are
subclinical.
Incidence: Mumps is primarily a childhood disease with
about 95% of all cases occurring in children under 15
years of age. The incidence of mumps has shown a
dramatic decrease since the introduction of the mumps
vaccine in 1967.  This virus is highly contagious.  Neonates
receive passive immunity from the mother and the high
incidence of childhood mumps infections makes adult
cases rare.
Pathogenesis:  The virus usually enters the body through
the upper respiratory tract and infects regional lymph
nodes.   Viremia results from spread of the virus from the
lymph nodes to the bloodstream.  The mumps virus
spreads to the meninges, salivary glands (necrosis,
interstit ial edema, inflammation, and lymphocytic
infiltration), testes, pancreas, ovaries, kidneys (virtually
every case shows impaired renal function), thyroid, eyes,
and mammary glands (occasionally).
The mumps virus has a tropism for glandular tissue and
also is neurotropic, resulting in meningitis, encephalitis,
myelitis, polyneuritis, polyradiculitis, and cranial neuritis.
There also is frequent renal involvement.
Manifestations:  Mumps is often asymptomatic.  A clinically
nondescript, febrile upper-respiratory disease is also
common in infants and preschoolers.
A. Incubation period: 14-25 days with average of 18
days
B. Clinical presentation
1.    Approximately 30% of cases are asymptomatic.
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2. In persons who have symptoms, the
illness has variable severity.
3. Prodrome (does not always occur):
myalgia, anorexia, malaise, and a low-
grade fever with only parotitis.
C. Most common presentation:
1. Parotitis
a. Within the 1st day after the nonspecific
prodrome, the child may complain of
earache. Pain is localized near thelobe
of the ear, worsened by chewing
movements.
b. Within the 2nd day after the nonspecific
prodrome, parotid gland swelling is
visible and then rapidly enlarges within
the next 1-3 days.  During this period,
pain and tenderness may be severe.
Once the swelling reaches maximum,
the symptoms decrease.  The swelling
decreases over a period of 3-7 days.
c. The parotid gland feels jellylike. The
overlying skin is not usually warm to the
touch as it is in bacterial parotitis.
d. Orifices of Wharton’s and/or Stensen’s
ducts become red and swollen with
pinpoint petechial hemorrhages. If
obstruction of these inflamed ducts by
edema or cellular debris occur, chewing
or drinking may be very painful.
e. Parotitis can be unilateral or bilateral.  If
it is bilateral, one parotid gland enlarges
first and then the second enlarges a few
days later.  Occasionally, both sides
enlarge simultaneously.
f. Fever subsides after 1-6 days and
becomes normal BEFORE the parotid
swelling disappears.
2. Most frequent of the lesser common
presentations
a. Enlargement of parotid and submaxillary
salivary glands or enlargement of only
the submaxillary gland.  Swelling will
spread over the mandible onto the cheek
and downward toward the neck. In this
case, mumps will be indistinguishable
from cervical lymphadenitis.
b. Enlargement of all 3 salivary glands
(unilaterally or bilaterally): Parotid,
submaxillary, and sublingual salivary
glands. The sublingual salivary glands
are the least commonly involved glands
in mumps. If they enlarge, there will be
swelling in the submental regions and
on the floor of the mouth.
c. Epididymo-orchitis
    2nd most common manifestation of
     mumps in an adult males.
    Usually follows parotitis but may occur
     before parotitis or may even occur
     without parotitis.
 Usually unilateral.
d. Meningoencephalitis
 Occurs in about 10% of all cases.
   Usually follows parotitis by 3-10 days
    but may occur before parotitis or may
    even occur without parotitis.
When to Think of Mumps:
         A. There is a history of exposure to mumps 2-3
weeks before onset of illness.
        B. There is a compatible clinical picture of parotitis
or other glandular involvement.
        C. There are signs of aseptic meningoencephalitis
or, in a male, epididymo-orchitis.
Differential  Diagnosis for Pediatric Parotid Disease:
A. Mumps may be confused with various conditions
affecting the parotid glands or neighboring lymph
nodes:
1.      Anterior cervical or preauricular lymphadenitis
               with surrounding edema:
a. A swollen parotid gland from mumps can
be identified by its characteristic location,
consistency and outline.  The parotid
glands will have a brawny consistency,
a well-defined posterior border, and an
ill-defined anterior and inferior borders.
b. Enlarged preauricular or posterior
auricular lymph nodes have a well-
defined, discrete borders, are firm and
do not have the characteristic anatomic
location of the parotid gland to the ear.
c. An important point to remember is that
in parotitis the small hollow just under
the ear disappears but does not
disappear if there is lymphadenitis.
B. Other Causes of Parotitis or Enlarged Parotid
Gland
1.     Bacterial parotitis
        a. The skin over the parotid gland is usually
red and hot.
b. The parotid gland is exquisitely tender.
c. There is often pus from Stensen’s duct if
the parotid gland is massaged.
d. This is usually caused by S. aureus, but
may also be caused by other bacteria.
       2. Recurrent parotitis - Frequent recurrent
swelling of the parotid gland (cause
unknown).
       3. Obstructive parotitis - Due to a calculus that
obstructs Stensen’s duct.  This is usually
recurrent.
               4. Parotitis due to other viral infections
               5. Coxsackie virus
               6. Parainfluenza 3
               7. Hemangiomas
               8. Lymphagiomas
               9. Benign and malignant and mixed tumors
             10. Sjorgren’s syndrome
             11. Sarcoidosis
             12. HIV
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Year-to-Date Summary of Selected Reportable Conditions - January 1, 2006 - August 14, 2006 *
Condition Confirmed Probable Total 
Anthrax 0 * 0 
Arboviral Neuroinvasive Disease 0 0 0 
Botulism 0 0 0 
Brucellosis 2 0 2 
Campylobacter enteriditis 153 0 153 
Cholera 0 * 0 
Creutzfeldt-Jakob disease (age <55 years) 0 0 0 
Cryptosporidiosis 91 * 91 
Cyclosporiasis 4 * 4 
Dengue 0 1 1 
Diphtheria 0 0 0 
Ehrlichiosis 1 4 5 
Enterohemorrhagic E. Coli (includes O157:H7) 7 0 7 
Giardiasis 75 1 76 
Glanders 0 0 0 
Haemophilius influenzae, non-type b invasive disease 26 0 26 
Haemophilus influenzae type b, invasive disease 2 0 2 
Hantavirus 0 * 0 
Hemolytic uremic syndrome 1 0 1 
Hepatitis A, acute 19 * 19 
Hepatitis B, acute 65 * 65 
Hepatitis B, chronic 475 * 475 
Hepatitis C, acute 0 * 0 
Hepatitis C, chronic or past 2,161 1,299 3,460 
Hepatitis D 1 * 1 
Hepatitis E 1 * 1 
Influenza, positive virus culture isolates 30 * 30 
Kawasaki disease 2 * 2 
Legionellosis 3 * 3 
Leprosy 0 * 0 
Leptospirosis 0 0 0 
Listeriosis 6 * 6 
Lyme disease 11 * 11 
Malaria 9 * 9 
Measles (rubeola) 0 0 0 
Meningitis, aseptic 78 * 78 
Meningococcal disease 17 0 17 
Mumps 4 0 4 
Pertussis 126 15 141 
Plague 0 0 0 
Poliomyelitis 0 0 0 
Psittacosis 0 0 0 
Q fever 0 0 0 
Rabies (human) 0 * 0 
Rocky Mountain Spotted Fever 2 30 32 
Rubella (includes congenital) 0 0 0 
Salmonellosis 667 2 669 
SARS 0 0 0 
Shigellosis 74 0 74 
Smallpox 0 0 0 
Staphylococcus aureus, vancomycin-resistant (VRSA/VISA) 0 * 0 
Streptococcus group A, invasive disease 57 * 57 
Streptococcus group B, age < 90 days 30 * 30 
Streptococcus pneumoniae, invasive 173 * 173 
Tetanus 1 * 1 
Toxic Shock (Staphylococcal or Streptococcal) 0 0 0 
Toxins 1 0 1 
Trichinosis 0 * 0 
Tularemia 0 0 0 
Typhoid Fever 0 0 0 
Typhus (scrub) fever 0 0 0 
Varicella 474 361 835 
Vibrio infections (non-cholera) 6 * 6 
Viral Hemorrhagic Fever 0 0 0 
Yellow Fever 0 0 0 
Yersiniosis 3 0 3 
    
* Probable case status is not allowed for this condition.    
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